Brain Cancer Clinical Trials in Pittsburgh

Showing 81-94 of 94 trials

AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors

NCT00326664

This phase I trial is studying the side effects and best dose of AZD2171 in treating young patients with recurrent, progressive, or refractory primary CNS tumors. AZD2171 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

Childhood Atypical Teratoid/Rhabdoid TumorChildhood Central Nervous System Germ Cell TumorChildhood Cerebral Anaplastic Astrocytoma+18 more

National Cancer Institute (NCI)55 participantsStarted Mar 2006

San Francisco, California, United States • Washington D.C., District of Columbia, United States • Chicago, Illinois, United States +8 more locations

WITHDRAWNPHASE1/PHASE2< 1 mile

Phase I/II Trial of Intracerebral IL13-PE38QQR Infusions in Pediatric Patients With Recurrent Malignant Glioma

NCT00378235

IL13-PE38QQR is an oncology drug product consisting of IL13 (interleukin-13) and PE38QQR (a bacteria toxin). IL3-PE38QQR is a protein that exhibits cell killing activity against a variety of IL13-receptor positive tumor cell lines indicating that it may show a therapeutic benefit. In reciprocal competition experiments, the interaction between IL13-PE38QQR and the IL13 receptors was shown to be highly specific for human glioma cells.

Recurrent Malignant Glioma

INSYS Therapeutics Inc

San Francisco, California, United States • Washington D.C., District of Columbia, United States • Chicago, Illinois, United States +7 more locations

AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors

Phase I/II Trial of Intracerebral IL13-PE38QQR Infusions in Pediatric Patients With Recurrent Malignant Glioma

Brain Cancer Trials in Other Cities

Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Infants With Malignant Brain or Spinal Cord Tumors

Carboplatin and Vincristine Plus Radiation Therapy Followed By Adjuvant Chemotherapy in Treating Young Patients With Newly Diagnosed CNS Embryonal Tumors

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Newly Diagnosed Brain Stem Glioma

Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma

Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma

A Study of XL765 (SAR245409) in Combination With Temozolomide With and Without Radiation in Adults With Malignant Gliomas

A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Malignant Glioma

A Study of 131I-TM601 in Adults With Recurrent Malignant Glioma

Study of Everolimus (RAD001) in Patients With Recurrent Glioblastoma Multiforme (GBM)

A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma

Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma Patients

A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma

Other Conditions in Pittsburgh